• Search

Discovery Stems From Here

Find your tools for building human cell-based models & screening assays

Axol uses human iPSCs to generate specific cell types
We do NOT use animal cells or embryonic stem cells (ESCs)

Welcome to Axol Bioscience


We provide highly validated human iPSC-derived cells and primary cells from healthy donors and patients of specific disease backgrounds, together with optimized media and growth supplements. Axol aims to develop the best human cell biology research tools to advance medical research and drug discovery. Combining our passion for science with quality, innovation and customer service, we deliver robust and reliable products that our customers need to advance their research faster.

Latest News

  • Neuroimmunology Drug Development (NIDD) 2019

    Our Booth #760
    Our Workshop (find out more)
    Our Poster (find out more)

  • Axol Bioscience launch human iPSC-derived Microglia

    Cambridge, UK – (6th December 2018) – Axol Bioscience, the human cell culture specialist, is launching a new line of Human induced Pluripotent Stem Cells (iPSC)-derived Microglia for the consistent and reproducible study of neuroglia and their involvement in neurodegenerative diseases, including Alzheimer’s disease, multiple sclerosis and Parkinson’s disease.

  • Good Cell Culture Practice in Toxicology Seminar

    Axol Bioscience is presenting at the two-day seminar hold by Evercyte and Altetox in Vienna, from 30-31 October. Book your ticket today.

  • Three reasons why iPSC-derived atrial cardiomyocytes are poised to accelerate atrial fibrillation research

    Atrial fibrillation is estimated to affect around 6 million people in Europe, making it the most common arrhythmia observed in the clinic. The irregular heartbeat and disturbed electrical activity experienced by atrial fibrillation patients is commonly treated by surgical interventions such as pacemakers or the ablation of diseased tissue, or with non-selective class IC (Nav) and III (Kv) ion channel anti-arrhythmic drugs. However, these approaches can have serious side-effects, so extensive research has been devoted to better understand the cellular mechanisms behind the disease to develop safer and more effective treatments.

  • iPSC-derived atrial cardiomyocytes: a reproducible platform for translational disease insights

    Atrial fibrillation is the most common arrhythmia observed in the clinic, affecting 6 million patients in Europe and accounting for 30% of strokes. The prevalence of atrial fibrillation continues to grow due to an aging population and is expected to double over the next 50 years. Given the need to develop safer and more effective anti-arrhythmic therapeutics, considerable efforts have been made to understand the cellular mechanisms of the disease and translate this knowledge into innovative treatments.